nach oben

Erschienen in:

15.03.2018 | Original Article

Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma

verfasst von: Salvatore Grisanti, Deborah Cosentini, Valeria Tovazzi, Susanna Bianchi, Barbara Lazzari, Francesca Consoli, Elisa Roca, Alfredo Berruti, Vittorio D Ferrari

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Trabectedin is one of the few active agents in soft tissue sarcoma (STS) but hepatotoxicity is frequent and represents a dose-limiting factor. Protective strategies aiming at counteracting this important side effect have a crucial clinical impact. Due to its antioxidant properties, N-acetylcysteine (NAC) has a recognized hepatoprotective effect and this provides the rationale for testing NAC in the management of trabectedin-induced hepatotoxicity.

Methods

Patients with recurrent or metastatic soft tissue sarcoma, consecutively observed at our institution, who were considered eligible to trabectedin, received concomitant NAC if they had impaired hepatic or renal function at baseline or developed hepatotoxicity during treatment. The study aim was to retrospectively explore trabectedin administration in terms of number of cycles, mean dose, and dose intensity (DI) in patients who received NAC as compared with those who did not. Secondary end points were progression-free survival (PFS) and overall survival (OS).

Results

A total number of 18 patients were enrolled in this study. Nine received NAC and nine did not. The median number of administered trabectedin cycles, mean trabectedin dose/cycles, and median DI was comparable in the two groups (p = 0.450, p = 0.534, and p = 0.450, respectively). The PFS and OS curves overlapped.

Conclusion

This explorative study suggests that NAC can have a hepatoprotective activity in patients receiving trabectedin allowing to maintain an adequate dose intensity and continuative administration in patients with impaired liver and renal function or developing treatment-induced hepatotoxicity. A prospective randomized trial is warranted.

Gordon E.M., Sankhala K. K., Chawla N., Chawla S.P., (2016) Trabectedin for soft tissue sarcoma: current status and future perspectives, Springerlink.com

Del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gomez J, Parekh T, Park YC, McMeekin S (2013) Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 30:435CrossRefPubMed

Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65(2):166–176CrossRefPubMed

Haeussler U. Riedel M. Keller F., (2004) Free reactive oxygen species and nephrotoxicity of contrast agents. Kidney Blood Pressure Res Vol. 27, No. 3

Cai Z, Lou Q, Wang F, Li E, Sun J, Fang H, Xi J, Ju L (2015) N-acetylcysteine protects against liver injure induced by carbon tetrachloride via activation of the Nrf2/HO-1 pathway. Int J Clin Exp Pathol 8(7):8655–8662PubMedPubMedCentral

Donald S, Verschoyle RD, Greaves P, Orr S, Jimeno J, Gescher AJ (2004) Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol 53:305–312CrossRefPubMed

Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D’Incalci M, Gescher A, Casali PG (2006) Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 42:1484–1490CrossRefPubMed

Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188–4196CrossRefPubMed

Food US, Administration D (2015) Prescribing information of Yondelis. Reference ID 3837231

10.

Sales I, Dzierba AL, Smithburger PL, Rowe D, Kane-Gill SL (2013) Use of aacetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol 12:6–10PubMed

11.

Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH (1991) Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 20(10):1058–1063CrossRefPubMed

12.

Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Shah HA, Jafri W (2009) Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. Hepatol Int 3:563–570CrossRefPubMedPubMedCentral

13.

Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R (1991) Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 324:1852–1857 12CrossRefPubMed

14.

Zwingmann C, Bilodeau M (2006) Metabolic insights into the hepatoprotective effect of N-acetylcysteine in mouse liver. Hepatology 443:454–463CrossRef

15.

Rehman T, Fought J, Richard Solomon R (2008) N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 3(6):1610–1614CrossRefPubMedPubMedCentral

16.

Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ (2004) Prevention of radiocontrast nephropathy with n-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1–9CrossRefPubMed

17.

Graziani M., Antonilli L., Togna A.R., Grassi M.C., Badiani A., Saso L., (2016) Cardiovascular and hepatic toxicity of cocaine: potential beneficial effects of modulators of oxidative stress, Oxidative Medicine and Cellular Longevity Article ID 8408479;

18.

Demetri G.D., von Mehren M., Jones R.L., Hensley M.L., Schuetze S.M., Staddon A., Milhem M., Elias A., Ganjoo K., Tawbi H., Van Tine B.A., Spira A., Dean A., Khokhar N.Z., Park Y.C., Knoblauch R. E., Parekh T. V., Maki R. G., and Patel S. R. (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial J Oncol

19.

La Rowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A, Brady K (2006) Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 15(1):105–110CrossRef

Titel: Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma
verfasst von: Salvatore Grisanti
Deborah Cosentini
Valeria Tovazzi
Susanna Bianchi
Barbara Lazzari
Francesca Consoli
Elisa Roca
Alfredo Berruti
Vittorio D Ferrari
Publikationsdatum: 15.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4129-x

Springer Medizin

Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma